Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism
In summary, our study highlights that carrier-free SIL-SOR-MPs demonstrate the ability to reverse the progression of MASLD and present a promising therapeutic strategy.
Authors
- Haiping Wang (ORCID: https://orcid.org/0009-0009-4049-0466)
- Xiji Shu (ORCID: https://orcid.org/0000-0002-7415-6230)
- Xiaoying Hou (ORCID: https://orcid.org/0000-0002-9201-3970)
- Li Wang (ORCID: https://orcid.org/0000-0003-3881-3149)
- Yuchen Liu (ORCID: https://orcid.org/0000-0002-6517-0022)
- Feifei Han
- Sui Peng (ORCID: https://orcid.org/0000-0003-0342-6333)
- Limei Fan (ORCID: https://orcid.org/0000-0002-6505-4806)
- Binlian Sun (ORCID: https://orcid.org/0000-0002-3060-9867)
Institutions
- Jianghan University (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/ijn.s515107
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00